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Abstract
Dementia in children or young adults is most frequently caused by neuronal 
ceroidlipofuscinoses (NCL), a group of incurable lysosomal storage disorders 
linked by the accumulation of a characteristic intracellular storage material 
and progressive clinical deterioration, usually in combination with visual 
loss, epilepsy, and motor decline. The clinical characteristics can vary and 
the age at disease onset ranges from birth to over 30 years. Diagnosis of an 
NCL is difficult because of genetic heterogeneity with14 NCL forms (CLN1- 
CLN14) identified and a high phenotype variability. A new classification of the 
disorders is based on the affected gene and the age at disease onset and allows 
a precise and practicable delineation of every NCL disease. We present a clear 
diagnostic algorithm to identify each NCL form. A precise diagnosis is essential 
for genetic counseling of affected families and for optimizing palliative care. 
As patient management profits from recognizing characteristic complications, 
care supported by a specialized team of NCL clinicians is recommended. 
The development of curative therapies remains difficult as the underlying 
pathophysiological mechanism remains unclear for all NCL forms.
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Introduction
Unexpected loss of cognitive abilities (dementia) in young patients presents a 
diagnostic challenge. It is most frequently caused by neuronal ceroidlipofuscinoses 
(NCL), a group of lysosomal storage disorders linked by the accumulation of a 
characteristic storage material in neurons and other cell types, and a progressive 
clinical deterioration, usually in combination with visual loss, epilepsy, and motor 
decline (1). Diagnosis of an NCL is difficult because of a high number of different 
NCL-causing genes and significant genotype phenotype variability. Nevertheless, 
the specific diagnosis of an NCL disease can be made in a time- and cost-effective 
manner using very few diagnostic steps.
New nomenclature of NCL diseases 
Traditionally, NCL diseases were classified according to the age at disease onset 
into congenital, infantile, late infantile, juvenile, and adult forms and sometimes 
also according to the respective authors (Haltia-Santavuori, Jansky-Bielschowsky, 
Batten, Spielmeyer-Vogt, Kufs) (2). More recently it became clear that NCL 
diseases are much more heterogeneous than previously thought and that mutations 
in the same gene can lead to very different clinical courses (3, 4). Designations 
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such as “Finish” or “Turkish” NCL variants are also not 
useful any longer, as mutations in the respective genes 
have been shown to occur worldwide (5).The traditional 
nomenclature has therefore become obsolete and has 
recently been replaced by an internationally developed 
combined genetic and clinical classification of NCL 
disorders (table 1) (2). It classifies both the defective gene 
as well as the age at disease onset (congenital, infantile, 
late infantile, juvenile or adult). An exact diagnosis is 
essential for genetic counseling, sharing information 
regarding prognosis and optimal palliative care.
The genetic spectrum of NCL diseases 
To date, 14 different NCL forms have been To date, 
14 different NCL forms have been described (table1) 
(5-10). More NCL genes remain to be identified as in 
some patients mutations cannot be demonstrated in 
any of the known NCL genes although they present 
with typical NCL symptoms and characteristic cellular 
storage material. Intracellular localization and- if 
known- function of the defective NCL proteins are 
different: Four NCL types are caused by defects in 
lysosomal enzymes (CLN1, CLN2, CLN10, CLN13), 
others by defects in transmembrane proteins (CLN3, 
CLN6, CLN7, CLN8) (6). Also, mutations of an 
ATPase (CLN12) (9) or a potassium channel (CLN14) 
(11) seem to cause NCL disease. The CLN4 gene (also 
called DNAJC5) codes for a protein with putative 
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CLN1 disease, infantile 
CLN1 disease, late-infantile 




CLN2 disease, juvenile 204500 CLN2 (TPP1)
CLN3 disease, juvenile 204200 CLN3
CLN4 disease, adult (autosomal dominant) 162350 CLN4 (DNAJC5)
CLN5 disease, late-infantile 




CLN6 disease, adult (Kufs type A) 601780 CLN6




CLN10 disease, congenital 
CLN10 disease, late-infantile 
CLN10 disease, juvenile 
CLN10 disease, adult
610127 CLN10 (CTSD)
CLN11 disease, adult 138945 CLN11 (GRN)
CLN12 disease, juvenile (9) CLN12 (ATP13A2)
CLN13 disease, adult (Kufs type B) (8) CLN13 (CTSF)
CLN14 disease, infantile (11) CLN14 (KCTD7)
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function in synapses (10). The exact mechanism, 
how these defects lead to neurodegeneration, is still 
not understood. Despite their genetic heterogeneity, 
the different NCL diseases have clinically much in 
common.  This is important both for diagnosis and 
palliative treatment. Curative therapies do not yet exist 
for any NCL disease.
The clinical spectrum of NCL diseases 
In almost all NCL forms the patients initially present 
healthy and have a normal development. Main symptoms 
are a combination of dementia, visual loss,
epilepsy, and motor deterioration that progress slowly 
but inexorably. The age at disease onset can range from 
birth till young adulthood. The order in which symptoms 
occur is variable. In a young child, first symptoms are 
standstill and regression of psychomotor development, 
or intractable epilepsy. In a school child, first symptoms 
are mostly visual loss, followed by dementia. The 
different disease courses are described below (2).For 
diagnostic tests refer to table 2.
Table 2. Diagnostic Algorithm for NCL Diseases 
Clinical presentation Necessary diagnostic tests Possibly affected genes
Newborn
With epilepsy and microcephaly




(>6months) with developmental 
or regression and/or newly severe 
epilepsy of unknown cause
Enzyme testing for PPT1 and TPP1 (dry blood spots;
confirmation in leucocytes or fibroblasts)
PPT1 PPT1 deficient: CLN1
TPP1 TPP1 deficient: CLN2
If PPT1 and TPP1 enzyme normal: Electron microscopic 
examination (skin biopsy or lymphocytes): If storage 
material is present: genetic testing.
CLN5, CLN6, CLN7, CLN8, 
CLN14 (KCTD7)
School child
with visual loss and / or dementia 
and epilepsy
Search for lymphocyte vacuoles (light microscopy of 
blood smear). If lymphocyte vacuoles are present: genetic 
testing of the CLN3 gene
CLN3
If no lymphocyte vacuoles, enzyme testing for PPT1, TPP1 
and CtsD (see above)
PPT1 deficient: CLN1, 
TPP1 deficient: CLN2, CtsD 
deficient: CLN10
If PPT1 and TPP1 enzyme normal: Electron microscopic 
examination (skin biopsy or lymphocytes).
If storage material is present: genetic testing.
CLN5, CLN6, CLN7, CLN8, 
CLN12 (ATP13A2)
Young adult 
with non-specific mental, motor or 
behavioral abnormalities.
Enzyme testing for PPT1, TPP1 and CtsD (see above)
PPT1 deficient: CLN1, 
TPP1 deficient: CLN2, CtsD 
deficient: CLN10
If PPT1 and TPP1 enzyme activity is normal: Electron 
microscopic examination (skin biopsy or lymphocytes). If 
storage material is present: genetic testing (eventually in 
special cases even without detection of storage material), 
consider possible mode of inheritance.
If autosomal dominant:CLN4 
(DNAJC5)
If autosomal recessive: 
CLN6, CLN11
(GRN, CLN13 (CTSF)
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Congenital disease onset 
This is the only NCL form where patients are severely 
affected already at birth. Intrauterine or immediate 
postnatal onset of epileptic seizures as well congenital 
microcephaly should lead to the suspected diagnosis. 
Confirmation is based on demonstration of cathepsin 
D deficiency and a mutation in the CLN10 gene. The 
disease leads to death in early infancy.
Infantile disease onset 
First symptoms are standstill and subsequent regression 
of psychomotor development occurring at the age of 10-
18 months. These are followed by muscular hypotonia 
which may change to spasticity later on, as well as 
myoclonus and epilepsy. Fulminant brain atrophy leads 
to progressive microcephaly. The electroencephalogram 
(EEG) becomes flat. Visual contact is lost due to 
retinopathy. Diagnosis depends on demonstration of a 
lysosomal enzyme defect (PPT1) and a CLN1 mutation 
(see table 2). Death occurs in early childhood.
Late infantile disease onset 
In this age group, several different gene defects and 
enzyme  deficiencies may  be  responsible     (table  2). 
First symptoms such as muscular hypotonia, ataxia and 
developmental regression occur at the age of 2-3 years. 
At the same age, therapy-resistant epileptic seizures 
frequently appear. The EEG may show posterior spikes 
under slow photic stimulation in several NCL forms 
(CLN2, CLN5, CLN6) (Fig. 1). Cerebral and cerebellar 
atrophy are seen by cerebral magnetic resonance imaging 
(Fig. 2). Visual loss is often diagnosed with delay due to 
the severe neurologic deficits of the patients. Additional 
problems are increasing spasticity and non-epileptic 
myoclonus. Most patients live until the age of 10-15 
years.
Juvenile disease onset  
The  juvenile  disease  typically  starts  with  isolated 
visual  failure  due  to  retinal  degeneration  at  early 
school  age  (5-7  years).  An  early  ophthalmologic 
finding  is  the  extinguished  electroretinogram,  later 
also a pigmentary retinopathy with thinning of vessels 
(frequently mistaken for “retinitis pigmentosa”, Fig. 3). 
Most patients in this group have an underlying CLN3 
mutation and vacuolated lymphocytes in their peripheral 
blood  (Fig.  4).  Unexpected  difficulties with  abstract 
reasoning at school herald progressive dementia, grand 
mal  seizures  and  motor  difficulties appear, the  latter 
mostly of a parkinsonian type with small-stepped gait 
and rigor. Spasticity and myoclonus are rare but may 
develop late during the disease course. During puberty 
a psychoorganic syndrome may occur with attacks of 
fear, panic, and hallucinations or with depressive or 
aggressive mood changes. These disturbances are a 
particular challenge to psychiatric management. Older 
patients may suffer from cool, livid extremities due to 
sinus bradycardia or other circulatory disturbances. 
Improved palliative management (e.g., gastric feeding 
tube for swallowing difficulties) has increased life 
expectancy up to the age of 30 years and more.
Adult disease onset
The age at disease onset in adult NCL forms has a 
wide range with average around 39 years (12, 13). 
First symptoms are variable. Clinically, a type A (initial 
progressive myoclonus epilepsy, dementia and ataxia) 
and type B (initial behavioral abnormalities and motor 
problems) have been differentiated, both without visual 
problems  (12). The  identification  of  affected  genes 
as well as the number of diagnosed cases is currently 
increasing.
Special aspects of palliative therapy in NCL 
Palliative management of a patient with an NCL disease 
represents a significant challenge due to a number of 
clinical problems some of which are disease-specific. 
Moreover, recognition of some complications is difficult 
as most patients are not able anymore to communicate 
verbally at later stages of their disease. Episodes of 
apparent pain require thorough clinical examination. 
Abdominal pain may be caused by constipation due to 
disease-related intestinal hypomotility or inadequate 
nutrition, but many other causes must be considered, 
such as unnoticed bone fractures or renal calculi, which 
both are a frequent consequence of immobility. Attacks 
of exacerbated spasticity (“spastic crisis”) may caused 
by gastro-esophageal reflux or an acute event such as 
testicular torsion.
Collaboration with other physicians experienced in 
clinical NCL problems can help improving palliative 
medication. Table 3, which is based on the authors’ 
experience, gives an overview on palliative medication 
for treating the most common symptoms in NCL.
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Epilepsy 
Seizures   in   NCL   are   mostly   treatment-resistant. 
Some commonly used antiepileptic drugs may have 
unusual effects on a patient whose brain is undergoing 
a degenerative process. We suggest the following 
guidelines for treating seizures in NCL: 
(1) Complete absence of seizures or normalization of 
electroencephalogram are not realistic aims in NCL 
patients.
(2) The EEG in NCL serves mainly for monitoring.
Therapy should be adjusted to clinical symptoms.
(3) Therapy with more than two antiepileptic drugs may 
lead to irritating side effects rather than to reduction 
of seizures.
(4) Some antiepileptic drugs are recommended in NCL 
patients (valproate and lamotrigine, table 3), others 
may have negative effects on the disease course 
and should be avoided (carbamazepin, phenytoine, 
vigabatrin).
(5) “Use only as many drugs as are necessary and as few 
as possible.”
Myoclonus
Myoclonus is a symptom which is difficult to treat. 
Patients, however, frequently seem to be less disturbed 
by the myoclonic jerks than caregivers. Levetiracetame, 
zonisamide and piracetame are effective treatments 
(table 3). Benzodiazepins should be avoided. Some 
antiepileptic drugs can aggravate myoclonus. Therefore, 
reduction of the number of different medications may 
improve myoclonus.. 
Spasticity
Painful spasticity is another symptom which should be 
treated: Substances such as baclofen and are effective. 
Tetrahydrocannabinol may be used as add on medication 
(table 3). Benzodiazepin as well as tetrazepam seem to 
be less effective (less potency, negative effect on disease 
course, increased mucous secretion). Physical therapies 
and the search for any underlying trigger of spastic crises 
should always be considered.
Other problems
Diagnosis and treatment of tormenting 
psychopathological  symptoms such as sleep 
disturbances, fear, aggressive behaviour,  depression, 
and  hallucinations  represent special  challenges. 
Psychopharmacologic  medication should be given 
in collaboration with child neurologists and child 
psychiatrists, parents, and caregivers. Only this way, 
side effects of drugs as well as undetected causes
for fear and restlessness can be identified in time.
 Table 3. Overview on Medication for Palliative Therapies in NCL 
Symptom Substance Comment
Epilepsy* Valproate Advantage: mood stabilizing effect, useful in juvenile NCL patients with psychotic symptoms
Lamotrigine
Topiramate Increase dosage SLOWLY to minimize side effects such as speech 
disturbance (starting dose 0.5 mg/kg/d). Agitation may be a side effect. In 
this case discontinue the drug. 
Levetiracetame Severe agitation is a possible side effect in juvenile NCL. 
Diazepam, lorazepam Acute therapy of prolonged grand mal seizures 
Myoclonus Levetiracetame Also effective as anti-epileptic medication (especially in late infantile NCL)
Zonisamide
Piracetame High dosage required (300-350 mg/kg/d)
Spasticity Baclofen (1st choice) Frequently high dosagerequired
Tizanidine (2nd choice) Good effect also against dyskinesia
Tetrahydrocannabinol “Add-on” medication, increase dosage SLOWLY up to 0.07 mg/kg/d,
Botulinumtoxine Local application by injection to muscles; always accompanied by 
physical therapy
* Avoid overtreatment, as most seizures in NCL are treatment-resistant.
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Fig 1. Electroencephalogramm of a 5-year-old patient with CLN2 disease, late 
infantile, recorded under slow (1/sec) photic stimulation. Spikes over the occipital 
areas correspond to light flashes and illustrate increased neuronal excitability during 
this stage of the disease.
Fig 2. Magnetic resonance tomograms, T2-weighted, of a 5½-year-old child with 
CLN2 disease, late infantile. Cerebral and cerebellar atrophy is evident.
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Fig 3. Fundoscopic appearance of the retina of a patient with CLN3 disease, juvenile. 
Irregular pigment distribution and thin blood vessels are visible.
Fig 4. Vacuoles in the cytoplasm of a  peripheral blood lymphocyte from a patient 
with CLN3 disease, juvenile, routine blood smear.
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